1. Home
  2. CRSP vs DOCS Comparison

CRSP vs DOCS Comparison

Compare CRSP & DOCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.82

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Logo Doximity Inc.

DOCS

Doximity Inc.

HOLD

Current Price

$22.24

Market Cap

4.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
DOCS
Founded
2013
2010
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.5B
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
CRSP
DOCS
Price
$56.82
$22.24
Analyst Decision
Buy
Buy
Analyst Count
17
22
Target Price
$70.29
$47.59
AVG Volume (30 Days)
1.4M
2.5M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.17
EPS
N/A
0.88
Revenue
$289,590,000.00
$570,399,000.00
Revenue This Year
$743.50
$15.05
Revenue Next Year
$163.21
$8.98
P/E Ratio
N/A
$25.70
Revenue Growth
9169.85
19.98
52 Week Low
$33.03
$20.55
52 Week High
$78.48
$76.51

Technical Indicators

Market Signals
Indicator
CRSP
DOCS
Relative Strength Index (RSI) 65.66 36.56
Support Level $51.64 N/A
Resistance Level $60.63 $25.41
Average True Range (ATR) 2.28 1.21
MACD 1.17 0.07
Stochastic Oscillator 94.14 35.76

Price Performance

Historical Comparison
CRSP
DOCS

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About DOCS Doximity Inc.

Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.

Share on Social Networks: